SpectRx cervical cancer detection
This article was originally published in The Gray Sheet
Executive Summary
Grant of $690,000 from the National Cancer Institute, announced Sept. 13, will go toward completing a pivotal trial for SpectRx' noninvasive LightTouch cervical cancer detection technology. More than 1,100 women have been enrolled in the five-site trial, expected to complete enrollment in 2007. The firm will seek expedited PMA approval of LightTouch as a triage step for women with positive Pap or HPV tests to confirm whether colposcopy and biopsy are warranted. SpectRx has received a total of $3.2 mil. in NCI funding for the product...